blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3903841

EP3903841 - NOVEL TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES BIO MODULATED CERAMICS [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  18.02.2022
Database last updated on 14.06.2024
FormerThe application has been published
Status updated on  01.10.2021
Most recent event   Tooltip18.03.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Moroxite F AB
Kung Oskars väg 11 C
222 35 Lund / SE
[2022/13]
Former [2021/44]For all designated states
Moroxite AB
Brobyggargatan 4
298 31 Tollarp / SE
Inventor(s)01 / TÄGIL, Magnus
22465 Lund / SE
02 / RAINA, Deepak Bushan
22645 Lund / SE
03 / LIDGREN, Lars Åke Alvar
22460 Lund / SE
 [2021/44]
Representative(s)Zacco Denmark A/S
Arne Jacobsens Allé 15
2300 Copenhagen S / DK
[2021/44]
Application number, filing date21180185.712.04.2019
[2021/44]
Priority number, dateEP2018016871223.04.2018         Original published format: EP 18168712
[2021/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3903841
Date:03.11.2021
Language:EN
[2021/44]
Search report(s)(Supplementary) European search report - dispatched on:EP06.10.2021
ClassificationIPC:A61L27/42, A61L27/54, A61L27/58, A61K9/00, A61K9/14, A61K31/675, A61K33/06, A61K33/42, A61P31/04, A61P35/00, A61P19/10, A61P19/08, A61L27/20, A61L27/24, A61L27/36, A61L27/46
[2021/44]
CPC:
A61K31/675 (EP); A61K9/143 (EP,US); A61K31/4409 (US);
A61K31/65 (US); A61K31/7036 (US); A61K31/704 (EP,US);
A61K33/06 (EP); A61K33/42 (EP); A61K38/08 (US);
A61K51/1244 (US); A61K9/0019 (EP,US); A61K9/5115 (US);
A61L27/18 (US); A61L27/20 (EP,US); A61L27/24 (EP);
A61L27/3608 (EP,US); A61L27/365 (EP,US); A61L27/46 (EP,US);
A61L27/54 (EP,US); A61L27/58 (EP,US); A61P35/00 (EP);
A61L2400/06 (US); A61L2400/12 (US); A61L2430/02 (EP,US) (-)
C-Set:
A61K31/675, A61K2300/00 (EP);
A61K31/704, A61K2300/00 (EP);
A61K33/06, A61K2300/00 (EP);
A61K33/42, A61K2300/00 (EP);
A61L27/20, C08L1/26 (EP);
A61L27/20, C08L5/02 (EP);
A61L27/20, C08L5/08 (EP);
A61L27/20, C08L5/12 (EP);
A61L27/46, C08L1/26 (EP);
A61L27/46, C08L5/02 (EP);
A61L27/46, C08L5/08 (EP);
A61L27/46, C08L5/12 (EP)
(-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/12]
Former [2021/44]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:NEUARTIGER BEHANDLUNGSANSATZ DURCH GEZIELTE ABGABE BIOAKTIVER MOLEKÜLE UND BIOMODULIERTER KERAMIK[2021/44]
English:NOVEL TREATMENT APPROACH BY TARGETED DELIVERY OF BIOACTIVE MOLECULES BIO MODULATED CERAMICS[2021/44]
French:NOUVELLE APPROCHE DE TRAITEMENT PAR ADMINISTRATION CIBLÉE DE MOLÉCULES BIOACTIVES CÉRAMIQUES MODULÉES BIO[2021/44]
Examination procedure16.02.2022Amendment by applicant (claims and/or description)
16.02.2022Examination requested  [2022/12]
16.02.2022Date on which the examining division has become responsible
Parent application(s)   TooltipEP19718311.4  / EP3784303
Fees paidRenewal fee
18.06.2021Renewal fee patent year 03
21.03.2022Renewal fee patent year 04
22.03.2023Renewal fee patent year 05
18.03.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XY]US5716359  (OJIMA SATOSHI [JP], et al) [X] 1-3,5,7,10 * abstract * * column 5, lines 22-50 * [Y] 1-11;
 [XY]WO0002597  (GS DEV AB [SE], et al) [X] 1-11 * abstract * * examples 2-3 * * page 12, paragraph last - page 13, paragraph 3 * [Y] 1-11;
 [X]WO0195952  (SECR DEFENCE [GB], et al) [X] 1-5,7,8,10 * figures 1-7; claims 1-15 * * page 20, line 15 - page 31, line 5 *;
 [X]WO02080933  (ROYAL ALEXANDRA HOSP CHILDREN [AU], et al) [X] 1-4,7,8,10 * abstract * * page 11, lines 14-33 *;
 [XY]WO2007002085  (PEZESHKIAN ALEX AHMAD [US]) [X] 1-3,5,7,10 * paragraphs [0017] - [0020] - [0 86]; figures 7, 15 * [Y] 1-11;
 [XY]WO2009011774  (ILION MEDICAL LLC [US], et al) [X] 1-3,5,7,10 * abstract * * page 17, line 19 - page 18, line 14 * [Y] 1-11;
 [XY]US2009043389  (VUNJAK-NOVAKOVIC GORDANA [US], et al) [X] 1-3,5,7,10 * paragraphs [0035] - [0040] - [0 44]; figures 3-10; example 1 * [Y] 1-11;
 [X]  - RASMUS CLEEMANN ET AL, "Dose-Dependent Resorption of Allograft by rhBMP-2 Uncompensated by New Bone Formation-A Canine Study With Implants and Zoledronate", THE JOURNAL OF ARTHROPLASTY, AMSTERDAM, NL, (20180401), vol. 33, no. 4, doi:10.1016/j.arth.2017.11.019, ISSN 0883-5403, pages 1215 - 1221.e1, XP055518254 [X] 1-3,7,8,10 * abstract * * page 1216, column r, paragraph Graft Material * * page 1216, column r, paragraph Implants - page 1217, column l, paragraph Surgery * * page 1216, paragraph experimental design * * page 1216, paragraphs Graft mterial, implants *

DOI:   http://dx.doi.org/10.1016/j.arth.2017.11.019
 [Y]  - NEDIM GÜNES ET AL, "Systemic and local zoledronic acid treatment with hydroxyapatite bone graft: A histological and histomorphometric experimental study", EXPERIMENTAL AND THERAPEUTIC MEDICINE, GR, (20161007), vol. 12, no. 4, doi:10.3892/etm.2016.3685, ISSN 1792-0981, pages 2417 - 2422, XP055517906 [Y] 1-11 * the whole document *

DOI:   http://dx.doi.org/10.3892/etm.2016.3685
 [Y]  - MISTRY SURAJIT ET AL, "A novel, multi-barrier, drug eluting calcium sulfate/biphasic calcium phosphate biodegradable composite bone cement for treatment of experimental MRSA osteomyelitis in rabbit model", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (20160828), vol. 239, doi:10.1016/J.JCONREL.2016.08.014, ISSN 0168-3659, pages 169 - 181, XP029742995 [Y] 1-11 * abstract * * page 170, paragraphs 2.1, 2.2, * * page 171, paragraph 2.5 * * page 172, paragraph 2.10 *

DOI:   http://dx.doi.org/10.1016/j.jconrel.2016.08.014
 [Y]  - DEEPAK BUSHAN RAINA ET AL, "A Biphasic Calcium Sulphate/Hydroxyapatite Carrier Containing Bone Morphogenic Protein-2 and Zoledronic Acid Generates Bone", SCIENTIFIC REPORTS, (20160518), vol. 6, no. 1, doi:10.1038/srep26033, pages 1 - 13, XP055457462 [Y] 1-11 * abstract * * page 10, paragraph Materials *

DOI:   http://dx.doi.org/10.1038/srep26033
by applicantWO2008041909
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.